metformin has been researched along with Bile Duct Cancer in 15 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The work is aimed to estimate the change in risk of local people in the endemic area of cholangiocarcinoma in scenario that diabetic patients are treated with metformin in the highly endemic area of cancer in Thailand." | 7.96 | Decreased risk of cholangiocarcinoma in diabetic patients treated with metformin. ( Sookaromdee, P; Wiwanitkit, V, 2020) |
| " Previously, we reported that metformin amplified the inhibitory effect of ATO on intrahepatic cholangiocarcinoma (ICC) cells more significantly than other agents." | 7.85 | Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1. ( Dai, H; Ling, S; Shan, Q; Song, P; Wei, X; Xie, H; Xu, X; Yang, F; Zheng, S; Zhou, L; Zhuo, J, 2017) |
| " The combination of gemcitabine and cisplatin is the standard chemotherapy regimen for cholangiocarcinoma, but its benefit is limited." | 7.83 | Metformin potentiates the anticancer activities of gemcitabine and cisplatin against cholangiocarcinoma cells in vitro and in vivo. ( Chang, H; Gao, HJ; Li, HG; Liu, FF; Lu, J; Ma, CQ; Ma, JB; Song, X; Zhou, X; Zhu, HQ, 2016) |
| "The antidiabetic drug metformin exerts antineoplastic effects in many types of malignancies, however the effect of metformin on cholangiocarcinoma (CCA) still remains unclear." | 7.81 | Metformin inhibits tumor growth by regulating multiple miRNAs in human cholangiocarcinoma. ( Cui, Y; Gao, X; He, R; Jiang, X; Kang, P; Li, D; Li, F; Ma, N; Wan, M; Wang, D; Wang, Y; Zhang, F; Zhao, R; Zhou, Q, 2015) |
| "Metformin is an oral anti-hyperglycemic agent, which is the most commonly prescribed medication in the treatment of type-2 diabetes mellitus." | 6.52 | Benefits of Metformin Use for Cholangiocarcinoma. ( Chavengkun, W; Eksanti, T; Kaewpitoon, N; Kaewpitoon, SJ; Kompor, P; Kootanavanichpong, N; Kujapun, J; Loyd, RA; Matrakool, L; Norkaew, J; Padchasuwan, N; Panpimanmas, S; Phatisena, T; Pholsripradit, P; Ponphimai, S; Rujirakul, R; Tongtawee, T, 2015) |
| "Metformin is a potent antiproliferative and anti-metastatic agent against human CCA cells." | 5.46 | Metformin Exerts Antiproliferative and Anti-metastatic Effects Against Cholangiocarcinoma Cells by Targeting STAT3 and NF-ĸB. ( Cha'on, U; Saengboonmee, C; Sawanyawisuth, K; Seubwai, W; Wongkham, C; Wongkham, S, 2017) |
| "Metformin is an oral anti-hyperglycemic agent of the biguanide family, which is used first-line for type II diabetes with few side-effects." | 5.40 | Metformin inhibits proliferation and enhances chemosensitivity of intrahepatic cholangiocarcinoma cell lines. ( Dong, C; Fan, N; Feng, T; Ke, Q; Li, L; Li, Y; Li, Z; Ling, S; Wang, C; Wang, L; Xu, F, 2014) |
| "The work is aimed to estimate the change in risk of local people in the endemic area of cholangiocarcinoma in scenario that diabetic patients are treated with metformin in the highly endemic area of cancer in Thailand." | 3.96 | Decreased risk of cholangiocarcinoma in diabetic patients treated with metformin. ( Sookaromdee, P; Wiwanitkit, V, 2020) |
| " Previously, we reported that metformin amplified the inhibitory effect of ATO on intrahepatic cholangiocarcinoma (ICC) cells more significantly than other agents." | 3.85 | Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1. ( Dai, H; Ling, S; Shan, Q; Song, P; Wei, X; Xie, H; Xu, X; Yang, F; Zheng, S; Zhou, L; Zhuo, J, 2017) |
| " The combination of gemcitabine and cisplatin is the standard chemotherapy regimen for cholangiocarcinoma, but its benefit is limited." | 3.83 | Metformin potentiates the anticancer activities of gemcitabine and cisplatin against cholangiocarcinoma cells in vitro and in vivo. ( Chang, H; Gao, HJ; Li, HG; Liu, FF; Lu, J; Ma, CQ; Ma, JB; Song, X; Zhou, X; Zhu, HQ, 2016) |
| "The antidiabetic drug metformin exerts antineoplastic effects in many types of malignancies, however the effect of metformin on cholangiocarcinoma (CCA) still remains unclear." | 3.81 | Metformin inhibits tumor growth by regulating multiple miRNAs in human cholangiocarcinoma. ( Cui, Y; Gao, X; He, R; Jiang, X; Kang, P; Li, D; Li, F; Ma, N; Wan, M; Wang, D; Wang, Y; Zhang, F; Zhao, R; Zhou, Q, 2015) |
| "Metformin is an oral anti-hyperglycemic agent, which is the most commonly prescribed medication in the treatment of type-2 diabetes mellitus." | 2.52 | Benefits of Metformin Use for Cholangiocarcinoma. ( Chavengkun, W; Eksanti, T; Kaewpitoon, N; Kaewpitoon, SJ; Kompor, P; Kootanavanichpong, N; Kujapun, J; Loyd, RA; Matrakool, L; Norkaew, J; Padchasuwan, N; Panpimanmas, S; Phatisena, T; Pholsripradit, P; Ponphimai, S; Rujirakul, R; Tongtawee, T, 2015) |
| "Metformin was not associated with BTC risk (HR, 0." | 1.72 | Aspirin, Statins, Non-aspirin NSAIDs, Metformin, and the Risk of Biliary Cancer: A Swedish Population-Based Cohort Study. ( Borad, MJ; Brusselaers, N; Harmsen, WS; Marcano-Bonilla, L; Patel, T; Petersen, GM; Roberts, LR; Sadr-Azodi, O; Schleck, CD; Therneau, TM, 2022) |
| "Metformin is a potent antiproliferative and anti-metastatic agent against human CCA cells." | 1.46 | Metformin Exerts Antiproliferative and Anti-metastatic Effects Against Cholangiocarcinoma Cells by Targeting STAT3 and NF-ĸB. ( Cha'on, U; Saengboonmee, C; Sawanyawisuth, K; Seubwai, W; Wongkham, C; Wongkham, S, 2017) |
| "Metformin is an oral anti-hyperglycemic agent of the biguanide family, which is used first-line for type II diabetes with few side-effects." | 1.40 | Metformin inhibits proliferation and enhances chemosensitivity of intrahepatic cholangiocarcinoma cell lines. ( Dong, C; Fan, N; Feng, T; Ke, Q; Li, L; Li, Y; Li, Z; Ling, S; Wang, C; Wang, L; Xu, F, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (66.67) | 24.3611 |
| 2020's | 5 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Marcano-Bonilla, L | 1 |
| Schleck, CD | 1 |
| Harmsen, WS | 2 |
| Sadr-Azodi, O | 1 |
| Borad, MJ | 1 |
| Patel, T | 1 |
| Petersen, GM | 1 |
| Therneau, TM | 2 |
| Roberts, LR | 3 |
| Brusselaers, N | 1 |
| Laffusa, A | 1 |
| Ciaccio, A | 1 |
| Elvevi, A | 1 |
| Gallo, C | 1 |
| Ratti, L | 1 |
| Invernizzi, P | 1 |
| Massironi, S | 1 |
| Sookaromdee, P | 1 |
| Wiwanitkit, V | 1 |
| Raggi, C | 1 |
| Taddei, ML | 1 |
| Sacco, E | 1 |
| Navari, N | 1 |
| Correnti, M | 1 |
| Piombanti, B | 1 |
| Pastore, M | 1 |
| Campani, C | 1 |
| Pranzini, E | 1 |
| Iorio, J | 1 |
| Lori, G | 1 |
| Lottini, T | 1 |
| Peano, C | 1 |
| Cibella, J | 1 |
| Lewinska, M | 1 |
| Andersen, JB | 1 |
| di Tommaso, L | 1 |
| Viganò, L | 1 |
| Di Maira, G | 1 |
| Madiai, S | 1 |
| Ramazzotti, M | 1 |
| Orlandi, I | 1 |
| Arcangeli, A | 1 |
| Chiarugi, P | 1 |
| Marra, F | 1 |
| Casadei-Gardini, A | 1 |
| Filippi, R | 1 |
| Rimini, M | 1 |
| Rapposelli, IG | 1 |
| Fornaro, L | 1 |
| Silvestris, N | 1 |
| Aldrighetti, L | 1 |
| Aimar, G | 1 |
| Rovesti, G | 1 |
| Bartolini, G | 1 |
| Vivaldi, C | 1 |
| Brunetti, O | 1 |
| Sperti, E | 1 |
| La Face, R | 1 |
| Ratti, F | 1 |
| Andrikou, K | 1 |
| Valgiusti, M | 1 |
| Bernardini, L | 1 |
| Argentiero, A | 1 |
| Fenocchio, E | 1 |
| Frassineti, GL | 1 |
| Cesario, S | 1 |
| Giovannelli, F | 1 |
| Quarà, V | 1 |
| Leone, F | 1 |
| Cascinu, S | 1 |
| Wandee, J | 2 |
| Prawan, A | 2 |
| Senggunprai, L | 2 |
| Kongpetch, S | 2 |
| Tusskorn, O | 1 |
| Kukongviriyapan, V | 2 |
| Ling, S | 2 |
| Feng, T | 1 |
| Ke, Q | 1 |
| Fan, N | 1 |
| Li, L | 1 |
| Li, Z | 1 |
| Dong, C | 1 |
| Wang, C | 1 |
| Xu, F | 1 |
| Li, Y | 1 |
| Wang, L | 1 |
| Jiang, X | 1 |
| Ma, N | 1 |
| Wang, D | 1 |
| Li, F | 1 |
| He, R | 1 |
| Li, D | 1 |
| Zhao, R | 1 |
| Zhou, Q | 1 |
| Wang, Y | 1 |
| Zhang, F | 1 |
| Wan, M | 1 |
| Kang, P | 1 |
| Gao, X | 1 |
| Cui, Y | 1 |
| Yang, Z | 1 |
| Zhang, X | 1 |
| Roberts, RO | 2 |
| Chaiteerakij, R | 2 |
| Kaewpitoon, SJ | 1 |
| Loyd, RA | 1 |
| Rujirakul, R | 1 |
| Panpimanmas, S | 1 |
| Matrakool, L | 1 |
| Tongtawee, T | 1 |
| Kootanavanichpong, N | 1 |
| Kompor, P | 1 |
| Chavengkun, W | 1 |
| Kujapun, J | 1 |
| Norkaew, J | 1 |
| Ponphimai, S | 1 |
| Padchasuwan, N | 1 |
| Pholsripradit, P | 1 |
| Eksanti, T | 1 |
| Phatisena, T | 1 |
| Kaewpitoon, N | 1 |
| Zhu, HQ | 1 |
| Ma, JB | 1 |
| Song, X | 1 |
| Gao, HJ | 1 |
| Ma, CQ | 1 |
| Chang, H | 1 |
| Li, HG | 1 |
| Liu, FF | 1 |
| Lu, J | 1 |
| Zhou, X | 1 |
| Saengboonmee, C | 1 |
| Seubwai, W | 1 |
| Cha'on, U | 1 |
| Sawanyawisuth, K | 1 |
| Wongkham, S | 1 |
| Wongkham, C | 1 |
| Xie, H | 1 |
| Yang, F | 1 |
| Shan, Q | 1 |
| Dai, H | 1 |
| Zhuo, J | 1 |
| Wei, X | 1 |
| Song, P | 1 |
| Zhou, L | 1 |
| Xu, X | 1 |
| Zheng, S | 1 |
| Yang, JD | 1 |
| Slettedahl, SW | 1 |
| Mettler, TA | 1 |
| Fredericksen, ZS | 1 |
| Kim, WR | 1 |
| Gores, GJ | 1 |
| Olson, JE | 1 |
2 reviews available for metformin and Bile Duct Cancer
| Article | Year |
|---|---|
Impact of metformin on the incidence of human cholangiocarcinoma in diabetic patients: a systematic review and meta-analysis.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Diabetes Mellitus; Diabetes Melli | 2023 |
Benefits of Metformin Use for Cholangiocarcinoma.
Topics: Animals; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Humans; Hypoglycemic Age | 2015 |
13 other studies available for metformin and Bile Duct Cancer
| Article | Year |
|---|---|
Aspirin, Statins, Non-aspirin NSAIDs, Metformin, and the Risk of Biliary Cancer: A Swedish Population-Based Cohort Study.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bile Duct Neoplasms; Bile Ducts, Intra | 2022 |
Decreased risk of cholangiocarcinoma in diabetic patients treated with metformin.
Topics: Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Diabetes Mellitus, Type 2; Endemic Diseas | 2020 |
Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma.
Topics: Animals; Bile Duct Neoplasms; Carcinogenesis; Cell Line, Tumor; Cholangiocarcinoma; Electron Transpo | 2021 |
Effects of Metformin and Vitamin D on Clinical Outcome in Cholangiocarcinoma Patients.
Topics: Bile Duct Neoplasms; Cholangiocarcinoma; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Mal | 2021 |
Metformin enhances cisplatin induced inhibition of cholangiocarcinoma cells via AMPK-mTOR pathway.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Cell Cycle; Ce | 2018 |
Metformin sensitizes cholangiocarcinoma cell to cisplatin-induced cytotoxicity through oxidative stress mediated mitochondrial pathway.
Topics: Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Cisplat | 2019 |
Metformin inhibits proliferation and enhances chemosensitivity of intrahepatic cholangiocarcinoma cell lines.
Topics: AMP-Activated Protein Kinase Kinases; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumo | 2014 |
Metformin inhibits tumor growth by regulating multiple miRNAs in human cholangiocarcinoma.
Topics: Animals; Antineoplastic Agents; Bile Duct Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell | 2015 |
Metformin does not improve survival of cholangiocarcinoma patients with diabetes.
Topics: Aged; Bile Duct Neoplasms; Cholangiocarcinoma; Diabetes Complications; Diabetes Mellitus; Female; Hu | 2016 |
Metformin potentiates the anticancer activities of gemcitabine and cisplatin against cholangiocarcinoma cells in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bile Duct Neoplasms; Cell Line, | 2016 |
Metformin Exerts Antiproliferative and Anti-metastatic Effects Against Cholangiocarcinoma Cells by Targeting STAT3 and NF-ĸB.
Topics: AMP-Activated Protein Kinases; Anoikis; Antineoplastic Agents; Bile Duct Neoplasms; Cell Line, Tumor | 2017 |
Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1.
Topics: AMP-Activated Protein Kinases; Animals; Arsenic Trioxide; Arsenicals; Bile Duct Neoplasms; Cell Line | 2017 |
Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk.
Topics: Adult; Aged; Aged, 80 and over; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Case-Control Studies; | 2013 |